MET and neoplasm: Cabozantinib demonstrates immunomodulatory activity and targets multiple receptor tyrosine kinases involved in tumour pathogenesis, including the pro-angiogenic growth factor receptors VEGFR and MET, as well as the TAM family of kinases (TYRO3, AXL, MER), which contribute to immunosuppression in the tumour microenvironment.29